Find your next paid study

University of PennsylvaniaNCT07199764

Solid Tumors With HRAS AlterationsNon Small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)+4 more

Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors

This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and …

Kura Oncology, Inc.NCT06026410

~$10 – $8,750

Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations

The purpose of this study is to assess percentage reduction in the of urine NTX and serum CTX , in patients with NSCLC and bone metastases 1) with actionable d…

Carcinoma, Non-Small-Cell Lung

University of Colorado, DenverNCT03958565

Phase 2

Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)

To learn if belzutifan can help to control the disease in patients with metastatic RCC who are considered candidates for active surveillance and have not under…

Active SurveillanceClear Cell Renal Cell Carcinoma

M.D. Anderson Cancer CenterNCT07023432

Observational

Golf Recreational Exercise for Enhanced Survivorship in Prostate Cancer Survivors Undergoing Hormone Therapy (GREENS)

This clinical trial evaluates a golf recreational exercise program for enhancing survivorship in underrepresented prostate cancer survivors. Golf is a multimod…

Localized Prostate CarcinomaLocally Advanced Prostate CarcinomaStage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8+2 more

University of Southern CaliforniaNCT06500169

Phase 2

A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small…

Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

SWOG Cancer Research NetworkNCT05642572

~$10 – $7,500

Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)+1 more

Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG 12D-Mutant Solid Tumors

This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

Revolution Medicines, Inc.NCT06040541

~$10 – $8,750

Phase 2

A Single-arm, Open-label, Phase II Trial of Cemiplimab Plus Gemcitabine as Second-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Harboring SWItch/Sucrose Non-Fermentable (SWI/SNF) Alterations.

This is a Phase 2 trial evaluating the combination of cemiplimab with the standard of care chemotherapy agent gemcitabine for the treatment of patients with me…

Pancreatic Ductal Adenocarcinoma (mPDAC)

University of California, San DiegoNCT06790602

Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Longitudinal Prospective RWE Study (MYLUNG Consortium Part 3: Observational Study)

This longitudinal study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and…

Carcinoma, Non-Small-Cell Lung

US Oncology ResearchNCT05885698

~$10 – $1,125

Advanced or Metastatic Adrenocortical CarcinomaMetastatic Castration-resistant Prostate Cancer

A Phase 1, First-in-human (FIH), Multicenter, Open-label Trial of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma (ACC) and Metastatic Castration-resistant Prostate Cancer (mCRPC)

This FIH study is designed to assess the safety, tolerability, and preliminary efficacy signals of DS9051b in participants with ACC and mCRPC.

Daiichi SankyoNCT07189403

~$10 – $7,500

Non-Small Cell Lung CancerNSCLCPDAC - Pancreatic Ductal Adenocarcinoma+11 more

A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers

A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresect…

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)NCT06917079

~$10 – $8,750

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients

This study is being done to determine if there is a pattern associated with response to endocrine therapy alone and in combination with CDK4/6 inhibitor used f…

HER2-negative Breast CancerHormone-receptor-positive Breast CancerMetastatic Breast Cancer+6 more